FDA Says MOBIC Tablets Are Fine, Generics Keep Flowing Smoothly
Published Date: 4/21/2025
Notice
Summary
The FDA says MOBIC tablets (7.5 mg and 15 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price jumps. If you use or sell MOBIC, things will keep running smoothly with no surprise changes.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic MOBIC Approvals Continue
The FDA determined that MOBIC (meloxicam) tablets, 7.5 mg and 15 mg, were not withdrawn from sale for reasons of safety or effectiveness. Because of that finding, the FDA will not start procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to these products and will continue to approve ANDAs that refer to them if they meet legal and regulatory requirements. This lets the FDA keep approving generic versions, helping patients and pharmacies avoid shortages or sudden price increases.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-06781, National Vaccine Injury Compensation Program List of Petitions Received
The government just shared a list of new claims from people asking for vaccine injury compensation. If someone thinks a vaccine hurt them, they can file a petition, and a special court reviews these cases. This update keeps everyone in the loop about who’s asking for help and when, making sure the process stays fair and clear.
Next: 2025-06784, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; TREMFYA (guselkumab)
The FDA just gave the green light to TREMFYA (guselkumab) for a rare pediatric disease, using a special priority review voucher. This means faster approval for treatments that kids with rare diseases really need. The approval happened on March 20, 2025, helping patients get access sooner and encouraging companies to develop more rare disease medicines.